TGFB1 and myeloid sarcoma: While further studies are needed to test the role of TGFB1 in MS pathophysiology, it is important to notice that the monoclonal antibody Fresolimumab directed against all TGFB isoforms is available for clinical trials [90], cross the blood-brain barrier [91] and is currently under evaluation in patients suffering from systemic sclerosis [92].